Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  American Journal of Cardiology

• Publication date

  2009-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.amjcard.2009.05.030PMID 19766755
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Intensive Glucose Lowering in Type 2 Diabetes

  2009cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Correction of HDL Dysfunction in Individuals With Diabetes and the Haptoglobin 2-2 Genotype

  2008cited by this paper
• Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

  2007cited by this paper
• Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin.

  2007cited by this paper
• IGF-1 Reduces Inflammatory Responses, Suppresses Oxidative Stress, and Decreases Atherosclerosis Progression in ApoE-Deficient Mice

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.

  2007cited by this paper
• Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.

  2007cited by this paper
• IGF-1 Reduces Inflammatory Responses, Suppresses Oxidative Stress, and Decreases Atherosclerosis Progression in ApoE-Deficient Mice

  2007cited by this paper
• Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.

  2007cited by this paper
• A review of human and analogue insulin trials.

  2007cited by this paper
• Early retinopathy progression in four randomized trials comparing insulin glargine and Nph insulin

  2007cited by this paper
• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

  2007cited by this paper
• Direct Medical Costs of Venous Thromboembolism and Subsequent Hospital Readmission Rates: An Administrative Claims Analysis From 30 Managed Care Organizations

  2007cited by this paper
• Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

  2006cited by this paper
• Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross‐over trial in people with Type 1 diabetes

  2006cited by this paper
• COMPARISON OF BASAL INSULIN ADDED TO ORAL AGENTS VERSUS TWICE - DAILY PREMIXED INSULIN AS INITIAL INSULIN THERAPY FOR TYPE 2 DIABETES

  2006cited by this paper
• The Treat-to-Target Trial and related studies.

  2006cited by this paper
• Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.

  2005cited by this paper
• Does Panic Disorder Increase the Risk of Coronary Heart Disease? A Cohort Study of a National Managed Care Database

  2005cited by this paper
• Unraveling Reaven's syndrome X: serum insulin-like growth factor-I and cardiovascular disease.

  2003cited by this paper
• Unraveling Reaven's syndrome X: serum insulin-like growth factor-I and cardiovascular disease.

  2003cited by this paper
• Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring.

  2002cited by this paper
• Heart Disease : A Population-Based Case-Control Study Low Serum Insulin-Like Growth Factor I Is Associated With Increased Risk of Ischemic

  2002cited by this paper
• Low Serum Insulin-Like Growth Factor I Is Associated With Increased Risk of Ischemic Heart Disease: A Population-Based Case-Control Study

  2002cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Effect of insulin on the insulin-like growth factor system in children with new-onset insulin-dependent diabetes mellitus.

  1995cited by this paper
• Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

  1992cited by this paper
• Why predictive indexes perform less well in validation studies. Is it magic or methods?

  1987cited by this paper
• A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

  1987cited by this paper
• Decisive factors in the tolbutamide controversy.

  1975cited by this paper

• Insulin Management in Patients With Diabetes Receiving Hemodialysis: Unanswered Questions and Way Forward.

  2023cites this paper
• The association of long‐acting insulin analogue use versus neutral protamine Hagedorn insulin use and the risk of major adverse cardiovascular events among individuals with type 2 diabetes: A population‐based cohort study

  2022cites this paper
• Léčba inzulinem a kardiovaskulární komplikace Insulin therapy and cardiovascular complications

  2018influential citation
• Treatment with insulin analogs and prevalence of cardiovascular complications in patients with type 1 diabetes

  2017cites this paper
• Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis

  2016cites this paper
• Treatment with insulin analogs, especially Glargine and Lispro, associates with better renal function and higher hemoglobin levels in Type 1 diabetic patients with impaired kidney function

  2016cites this paper
• Comparison of basal insulin therapies with regard to the risk of acute myocardial infarction in patients with type 2 diabetes: an observational cohort study

  2015cites this paper
• Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review

  2015cites this paper
• Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations

  2014influential citation
• Insulin analogs for the management of type 2 diabetes.

  2013cites this paper
• Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes

  2012influential citation
• İnsülin Analoglarinin Diyabetes Mellitus Tedavisindeki Rolü ve Faydalari Role and Benef its of Insulin Analogues in the Treatment of Diabetes Mellitus

  2012cites this paper
• Long-acting basal insulin analogs: latest developments and clinical usefulness

  2012cites this paper
• Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes.

  2011cites this paper
• Basal Insulin Treatment in Type 2 Diabetes

  2011cites this paper
• International Forum for the Advancement of Diabetes Research and Care, April 29–30, 2011, Athens, Greece

  2011influential citation
• Two‐year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes

  2011cites this paper
• Vascular Health and Risk Management Dovepress Insulin Therapy in Critically Ill Patients

  year unknowncites this paper
• O R I G I N a L I N V E S T I G a T I O N Open Access

  year unknowncites this paper